These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21896610)

  • 1. Evidence of comparative efficacy should have a formal role in European drug approvals.
    Sorenson C; Naci H; Cylus J; Mossialos E
    BMJ; 2011 Sep; 343():d4849. PubMed ID: 21896610
    [No Abstract]   [Full Text] [Related]  

  • 2. A new approach to drug development.
    Mayer D
    N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099949
    [No Abstract]   [Full Text] [Related]  

  • 3. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 4. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary: The balance between marketing and safety.
    Beard K
    BMJ; 2008 Dec; 337():a2996. PubMed ID: 19109322
    [No Abstract]   [Full Text] [Related]  

  • 6. [Marketing of pediatric drugs].
    Pabst JY
    Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
    [No Abstract]   [Full Text] [Related]  

  • 7. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 8. Biopharmaceuticals: recent approvals and likely directions.
    Walsh G
    Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viewpoint: Sir Richard Sykes, DSc, FRS, FMedSci. Interview by Ingrid Torjesen, BSc.
    Sykes R
    Circulation; 2006 Jun; 113(22):f85-6. PubMed ID: 16754809
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quicker drug approvals on the way for Europe.
    Davidson S
    Nat Biotechnol; 2001 Sep; 19(9):798-9. PubMed ID: 11533626
    [No Abstract]   [Full Text] [Related]  

  • 12. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 14. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf.
    Nesi T
    US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs.
    Reed SD; Anstrom KJ; Seils DM; Califf RM; Schulman KA
    Health Aff (Millwood); 2008; 27(5):w360-70. PubMed ID: 18682441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug approvals for 2002.
    Frantz S; Smith A
    Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
    [No Abstract]   [Full Text] [Related]  

  • 18. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.